8-K current report · filed Aug 11, 2026

Autolus Therapeutics plc (AUTL) 8-K Current Report: August 11, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2AUTL overview

Short answer

Autolus Therapeutics plc (AUTL) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Quarterly results for period ended June 30, 2026, accompanied by a corporate update.

Autolus Therapeutics plc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Quarterly results for period ended June 30, 2026, accompanied by a corporate update
  • Exhibit 99.1 contains the financial figures and management commentary investors need to assess performance

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation supports Autolus’s August 11, 2026 conference call on results for quarter ended June 30, 2026
  • Investors should review Exhibit 99.2 for management’s latest corporate and operating update

Item EX-99.1 · Exhibit EX-99.1

  • Q2 product revenue $45.7M, up 119% year-over-year and from $26.2M in Q1, confirming accelerating AUCATZYL commercial adoption
  • FY 2026 AUCATZYL revenue guidance raised to $140M-$150M from $120M-$135M, improving near-term growth visibility
  • Gross margin reached 55% versus 6% in Q1, supported by higher volumes, lower manufacturing costs and efficiency initiatives
  • Perceptive credit facility up to $250M, with $75M funded and $100M expected from initial tranches, extending cash runway into Q2 2028
  • Net loss narrowed to $39.1M from $47.9M, while cash, equivalents and marketable securities declined to $201.6M at June 30, 2026

Item EX-99.2 · Exhibit EX-99.2

  • Q2 2026 AUCATZYL net product revenue $45.7M, up 119% year over year
  • FY 2026 net product revenue guidance raised to $140M-$150M from $120M-$135M
  • U.S. commercial footprint reached 82 authorized treatment centers, exceeding the more than 80-center target
  • Gross margin improved to 55% in Q2 from 6% in Q1 and negative 9% in Q4 2025
  • Cash, equivalents and marketable securities $201.6M, with $100M credit facility proceeds, funding operations into Q2 2028

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Autolus Therapeutics plc 8-K filings

Get the next AUTL 8-K as it lands

Follow AUTL for push alerts, or ask the research agent what this filing means.